Table 4. – The association between ACEI/ARB use and disease severity in COVID-19 patients with hypertension.
| Antihypertensive treatment | |||||
|---|---|---|---|---|---|
|
| |||||
| Total (n=112) | ACEI/ARB treatment (n=20) | Other hypotensive drug (n=64) | No hypotensive treatment (n=28) | p-value | |
| Disease severity | 0.3487a | ||||
| Moderate | 20(17.8) | 3(15) | 11(17.2) | 6(21.4) | |
| Severe | 69(61.6) | 13(65) | 36(56.3) | 20(71.4) | |
| Critical | 23(19.3) | 4(20) | 17(26.6) | 2(7.1) | |
| Clinical outcome | 1.0000a | ||||
| Discharge | 92(82.1) | 16(80) | 49(76.6) | 27(96.4) | |
| Death | 20(17.9) | 4(20) | 15(23.4) | 1(3.6) | |
ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor blockers. a: R X C Chi-square test was used to analyze the difference between groups.